Inactive Instrument

Highlights Walmer Capital Corp Toronto S.E.

Equities

WALh

CA93266C1077

End-of-day quote Toronto S.E. Other stock markets
-	-

02-02	Nurexone Biologic Initiating European Orphan Drug Designation Process Following U.S. Grant; Comes After Its Shares Fell Near 5% Today	MT
01-17	NurExone and Inteligex Kick Off Chronic Spinal Cord Injury Research	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Nurexone Biologic Initiating European Orphan Drug Designation Process Following U.S. Grant; Comes After Its Shares Fell Near 5% Today	02-02	MT
NurExone and Inteligex Kick Off Chronic Spinal Cord Injury Research	01-17	MT
Nurexone Biologic Inc. and Inteligex Kick Off Chronic Spinal Cord Injury Research for Multi-Billion Dollar Healthcare Market	01-17	CI
NurExone Biologic Extends Spinal Cord Injury Therapy Portfolio With New RNA Sequences	11-29	MT
NurExone Biologic's Q3 Loss Widens; to Submit IND Application With FDA For ExoPTEN by Q4'24	11-24	MT
NurExone Biologic Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-24	CI
Nurexone Biologic Receives FDA Orphan-Drug Designation, Accelerating Development of Exopten Therapy for Acute Spinal Cord Injury Treatment	30/10/23	CI
NurExone Biologic Moving Forward Towards Human Clinical Trials, Completes Pre-IND Meeting With FDA For ExoPTEN Drug	13/09/23	MT
NurExone Biologic Inc. Moves Forward Towards Human Clinical Trials, Completes Pre-IND Meeting with FDA for Proprietary ExoPTEN Drug	13/09/23	CI
NurExone Biologic Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	28/08/23	CI
NurExone Biologic Inc. Announces Advancements in Extracellular Vesicles Functionality with Enhanced Potency and Cellular Uptake for potentially better drug delivery	20/07/23	CI
Nurexone Biologic Inc. Reports Positive Imaging Results from an Internal Preclinical Study of Its Investigational Drug ExoPTEN	22/06/23	CI
NurExone Biologic Inc. and Particle Metrix Announce Collaboration in Extracellular Vesicles Analysis Using Analytic Device	01/06/23	CI
NurExone Biologic Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	24/05/23	CI
NurExone Announces Interim Positive Results of Internal Preclinical Study of Proprietary ExoPTEN Drug	21/03/23	CI
NurExone Announces Interim Positive Results of Internal Preclinical Study of Proprietary ExoPTEN Drug	17/02/23	CI
NurExone Biologic Inc. is Developing ExoPTEN	13/02/23	CI
United States Patent Office Allows Patent to NurExone Biologic Inc	12/01/23	CI
Nurexone Biologic Successfully Demonstrates Its Patent-Pending Platform Technology for Loading Exosomes with Therapeutic Molecules	01/12/22	CI
Nurexone Biologic Successfully Demonstrates Its Patent-Pending Platform Technology for Loading Exosomes with Therapeutic Molecules	30/11/22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Walmer Capital Corp Toronto S.E.

Equities

WALh

CA93266C1077

Highlights

Filters